Evolving information has identified disease mechanisms and dysregulation of host biology
that might be targeted therapeutically in coronavirus disease 2019 (COVID-19). Thrombosis …

Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …

Background Ticagrelor may be a more effective antiplatelet therapy than aspirin for the
prevention of recurrent stroke and cardiovascular events in patients with acute cerebral …

MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by
specific gene modifications. Platelets are the major source for circulating miRNAs, with …

Mitochondria are central organelles in the homeostasis of the cardiovascular system via the
integration of several physiological processes, such as ATP generation via oxidative …

Peripheral artery disease (PAD) is a clinical manifestation of atherosclerotic disease with a
large-scale impact on the economy and global health. Despite the role played by platelets in …

Variants of transcription factor binding sites (TFBSs) constitute an important part of the
human genome. Current evidence demonstrates close links between nucleotides within …

Background: Current guidelines recommend dual antiplatelet therapy for the first 1 to 6
months after transcatheter aortic valve replacement (TAVR); however, recent studies have …

Background The potential benefits of individualized guided selection of antiplatelet therapy
over standard antiplatelet therapy in improving outcomes in patients undergoing …

Objective Antiplatelet drugs, such as Aspirin and Clopidogrel (Plavix) are effective in the
primary prevention of thromboembolic events. They are commonly used to reduce the risk of …